Ironwood shares edge up as June debt test draws investor attention
Ironwood Pharmaceuticals shares rose 0.9% to $3.43 Friday morning after executives spoke at the Jefferies Global Healthcare Conference. The company faces the June 15 maturity of its 1.50% convertible notes. Ironwood reported first-quarter U.S. LINZESS net sales up 97% to $272.5 million, with $220.5 million in cash at quarter’s end. The FDA recently expanded LINZESS use to children as young as 2.